Skip to main content


Success! India's First Mars Probe Is In Orbit And Working

Scientists cheered and the prime minister congratulated his country on navigating "a route known to very few" to reach the Red Planet something few other nations have accomplished.

Protesters in Savannah. Photo: Emily Jones

SSU Professor: Unlike In Ferguson, Savannah Residents Trust Officials

GPB's Emily Jones spoke with Savannah State Criminal Justice professor and former law enforcement officer Dr. Larry Stewart about the fatal police shooting of Charles Smith.

In This Year Of Ebola, A Montana YMCA Is Its Brother's Keeper

Big aid agencies are gearing up to help Ebola-ravaged countries. Small communities are also pitching in. The Y in Missoula, for example, is raising money to help the Y in Freetown.

Even When Abortion Is Illegal, The Market May Sell Pills For Abortion

An ulcer drug is dramatically changing the face of back-alley abortions in developing countries and cutting the rate of maternal deaths. Misoprostol is widely available even where abortion is banned.

A Place To Reflect During Jewish Holy Days That's Not A Temple

Sunset marks the start of the Jewish New Year as well as the 10 Days of Awe, when observant Jews reflect on the past year. Some are taking this reflection out of the temple and onto their tablets.

Al-Qaida's Khorasan Group Led By Hard-Core Fighters

The group, which was targeted by U.S. airstrikes in Syria last night, has been on the U.S. radar for a while. Intelligence officials say they have tracked its individual members for years.

Nobelist Muhammad Yunus: Be A Go-Getter, Not A Job Getter

The founding father of "microcredit" is helping to judge a contest with maxidollars: the Clinton Global Initiative's Hult Prize, granting $1 million to a new business idea that'll help the poor.

A Decline In Population In Macon Leads To An Increase In Blight

As people move away from Macon, many homes remain empty.

Insurers Cautious As Proton Beam Cancer Therapy Gains Popularity

Supporters of the controversial, high-priced treatment say routine coverage would help propel research that would support its use. Skeptics say that approach is backward.